Alpha memo: resveratrol exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either (a) weaken the Receipt 1 claim to 'the rat study was designed to test whether resveratrol attenuates exercise-induced inflammation, with results not verifiable from the supplied excerpt' OR (b) obtain the actual results section of the 2019 paper and cite a confirmed effect direction with effect size.
2. Resolve or explicitly flag the four-vs-six group count discrepancy in Receipt 1; do not silently choose one number.
3. Soften the 'why this is surprising' framing to acknowledge that species/dose/duration heterogeneity makes divergent outcomes expected rather than surprising.
4. Make the Receipt 2 endpoint ambiguity (truncated abstract) a first-class limitation rather than a parenthetical aside.

Major issues

• Receipt 1 does not provide a confirmed anti-inflammatory result in the supplied excerpt — only the study aim is stated. The memo's claim that rat work 'suggests resveratrol may attenuate exercise-induced inflammation' goes beyond what the receipt actually supports.
• The memo states the rats were 'divided into six groups' in the excerpt but the memo text says 'four labeled arms' — the memo silently resolves an internal discrepancy in the source rather than flagging it, and propagates the lower group count into its own claim.

Minor issues

• The title promises a 'cross-context evidence signal' but the memo could more explicitly frame this as a hypothesis-generating contrast rather than a signal.
• Receipt 2 abstract is truncated in the bundle, so the memo appropriately notes the exact blunted endpoint is not verifiable, but this should be stated more prominently as a limitation on the central contrast.
• The 'why this is surprising' framing implies genuine surprise; given heterogeneous species/dose/duration, the divergence is expected and the surprise framing mildly overstates novelty.

Reviewer note

The memo attempts a bounded cross-context contrast between a 2019 rat resveratrol/exercise study and a 2013 human RCT. The framing as a heterogeneous signal rather than overturning is appropriate, and the moderator hypotheses (species, age, dose, duration) are correctly identified as confounded. However, the Receipt 1 claim is not supported by the supplied excerpt, which contains only the study aim — no result direction, no effect size, no IL-6 outcome. The memo therefore builds half of its central contrast on a plausibility claim rather than a verified result. Additionally, the memo silently resolves a four-vs-six group count discrepancy from the source excerpt in favor of the lower number, which is a source-grounding defect. The Receipt 2 side is more grounded but the truncated abstract means the specific blunted endpoint is not verifiable, which the memo acknowledges only briefly. With these bounded edits — softening the rat claim to match what the receipt actually shows, explicitly flagging the group-count discrepancy, and promoting the endpoint ambiguity to a first-class limitation — the memo would be accept-quality. As submitted, it is revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis